

# Aaron N Winn, Mpp

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8572727/publications.pdf>

Version: 2024-02-01

63  
papers

1,492  
citations

361388  
20  
h-index

330122  
37  
g-index

65  
all docs

65  
docs citations

65  
times ranked

2493  
citing authors

#	ARTICLE	IF	CITATIONS
1	Financial burden and medication adherence among near-poor older adults in a pharmaceutical assistance program. <i>Research in Social and Administrative Pharmacy</i> , 2022, 18, 2517-2523.	3.0	3
2	The cost, survival, and quality of life implications of <scp>guidelineâ€discordant</scp> imaging for prostate cancer. <i>Cancer Reports</i> , 2022, 5, e1468.	1.4	5
3	The Longer-Term Benefits and Harms of Glucagon-Like Peptide-1 Receptor Agonists: a Systematic Review and Meta-Analysis. <i>Journal of General Internal Medicine</i> , 2022, 37, 415-438.	2.6	13
4	Opioid Prescribing and Use Among Cancer Survivors: A Mapping Review of Observational and Intervention Studies. <i>Journal of Pain and Symptom Management</i> , 2022, 63, e397-e417.	1.2	5
5	Longer-term Benefits and Risks of Sodium-Glucose Cotransporter-2 Inhibitors in Type 2 Diabetes: a Systematic Review and Meta-analysis. <i>Journal of General Internal Medicine</i> , 2022, 37, 439-448.	2.6	8
6	Racial Disparities in Patient Activation: The Role of Economic Diversity. <i>Western Journal of Nursing Research</i> , 2021, 43, 517-529.	1.4	3
7	Teleâ€ICUs for COVIDâ€19: A Look at National Prevalence and Characteristics of Hospitals Providing Teleintensive Care. <i>Journal of Rural Health</i> , 2021, 37, 133-141.	2.9	10
8	The Use and Concurrent Use of Side Effect Controlling Medications Among Women on Aromatase Inhibitors. <i>Journal of Women's Health</i> , 2021, 30, 131-136.	3.3	3
9	The costs of treating and not treating patients with chronic myeloid leukemia with tyrosine kinase inhibitors among Medicare patients in the United States. <i>Cancer</i> , 2021, 127, 93-102.	4.1	5
10	Impact of Pre-visit Contextual Data Collection on Patient-Physician Communication and Patient Activation: a Randomized Trial. <i>Journal of General Internal Medicine</i> , 2021, 36, 3321-3329.	2.6	9
11	The Role of Physician Professional Networks in Physiciansâ€™ Receipt of Pharmaceutical and Medical Device Industriesâ€™ Payments. <i>Journal of General Internal Medicine</i> , 2021, 36, 1858-1866.	2.6	5
12	Comparison of Anticancer Medication Use and Spending Under US Oncology Parity Laws With and Without Out-of-Pocket Spending Caps. <i>JAMA Health Forum</i> , 2021, 2, e210673.	2.2	0
13	Personal Payments from Pharmaceutical Companies to Authors of Oncology Clinical Practice Guidelines. <i>Oncologist</i> , 2021, 26, 771-778.	3.7	6
14	Pharmacy deserts and patients with breast cancer receipt of influenza vaccines. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2021, 61, e25-e31.	1.5	6
15	Clinician burnout during the COVID-19 pandemic before vaccine administration. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2021, 61, e71-e77.	1.5	27
16	An adapted two-step floating catchment area method accounting for urbanâ€rural differences in spatial access to pharmacies. <i>Journal of Pharmaceutical Health Services Research</i> , 2021, 12, 69-77.	0.6	6
17	Analysis of Clinician and Patient Factors and Completion of Telemedicine Appointments Using Video. <i>JAMA Network Open</i> , 2021, 4, e2132917.	5.9	29
18	Concurrent Opioid and Benzodiazepine Prescriptions Among Older Women Diagnosed With Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2020, 112, 765-768.	6.3	5

#	ARTICLE	IF	CITATIONS
19	Oral Oncology Parity Laws, Medication Use, and Out-of-Pocket Spending for Patients With Blood Cancers. <i>Journal of the National Cancer Institute</i> , 2020, 112, 1055-1062.	6.3	9
20	New-onset persistent opioid use following breast cancer treatment in older adult women. <i>Cancer</i> , 2020, 126, 814-822.	4.1	14
21	Response to Strassels and Durham. <i>Journal of the National Cancer Institute</i> , 2020, 112, 1280-1280.	6.3	0
22	Association of Current Opioid Use With Serious Adverse Events Among Older Adult Survivors of Breast Cancer. <i>JAMA Network Open</i> , 2020, 3, e2016858.	5.9	14
23	The impact of generic aromatase inhibitors on initiation, adherence, and persistence among women with breast cancer: Applying multi-state models to understand the dynamics of adherence. <i>Pharmacoepidemiology and Drug Safety</i> , 2020, 29, 550-557.	1.9	2
24	The association between drug industry payments and NCCN guideline panel membership.. <i>Journal of Clinical Oncology</i> , 2020, 38, 2068-2068.	1.6	3
25	The Impact of Previsit Contextual Data Collection on Patient-Provider Communication and Patient Activation: Study Protocol for a Randomized Controlled Trial. <i>JMIR Research Protocols</i> , 2020, 9, e20309.	1.0	3
26	Trends in a State Pharmaceutical Assistance Program for Low-income Older Adults in Wisconsin. <i>Innovations in Pharmacy</i> , 2020, 11, 9.	0.6	1
27	Factors associated with adjuvant endocrine therapy adherence in non-metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 533-533.	1.6	0
28	The impact of the use of opioids among older breast cancer survivors and adverse events.. <i>Journal of Clinical Oncology</i> , 2020, 38, 12098-12098.	1.6	0
29	Identifying Heterogeneous Treatment Effects of Drug Policy in Quasi-experimental Settings. <i>Current Epidemiology Reports</i> , 2019, 6, 373-379.	2.4	1
30	Assessing endometrial cancer risk among US women: long-term trends using hysterectomy-adjusted analysis. <i>American Journal of Obstetrics and Gynecology</i> , 2019, 221, 318.e1-318.e9.	1.3	30
31	Clinician Encouragement and Online Health Record Usage. <i>Journal of General Internal Medicine</i> , 2019, 34, 2345-2347.	2.6	4
32	Quantifying downstream impact of inappropriate staging imaging in a cohort of veterans with low- and intermediate-risk incident prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 145-149.	1.6	4
33	Evaluating the Strength of the Association Between Industry Payments and Prescribing Practices in Oncology. <i>Oncologist</i> , 2019, 24, 632-639.	3.7	33
34	Using Group-based Trajectory Models and Propensity Score Weighting to Detect Heterogeneous Treatment Effects. <i>Medical Care</i> , 2019, 57, 85-93.	2.4	11
35	Association of Use of Online Symptom Checkers With Patients' Plans for Seeking Care. <i>JAMA Network Open</i> , 2019, 2, e1918561.	5.9	54
36	More evidence on the limited impact of state oral oncology parity laws. <i>Cancer</i> , 2019, 125, 335-336.	4.1	3

#	ARTICLE	IF	CITATIONS
37	Making Sure We Don't Forget the Basics When Using Machine Learning. Journal of the National Cancer Institute, 2019, 111, 529-530.	6.3	2
38	Concurrent opioid and benzodiazepine use after breast cancer diagnosis.. Journal of Clinical Oncology, 2019, 37, 28-28.	1.6	0
39	Pharmaceutical Industry Payments and Oncologists' Selection of Targeted Cancer Therapies in Medicare Beneficiaries. JAMA Internal Medicine, 2018, 178, 854.	5.1	44
40	Cost-effectiveness of Continuous Glucose Monitoring for Adults With Type 1 Diabetes Compared With Self-Monitoring of Blood Glucose: The DIAMOND Randomized Trial. Diabetes Care, 2018, 41, 1227-1234.	8.6	66
41	Spending by Commercial Insurers on Chemotherapy Based on Site of Care, 2004-2014. JAMA Oncology, 2018, 4, 580.	7.1	19
42	Out-of-Pocket and Health Care Spending Changes for Patients Using Orally Administered Anticancer Therapy After Adoption of State Parity Laws. JAMA Oncology, 2018, 4, e173598.	7.1	31
43	Cost-effectiveness of Initiating an Insulin Pump in T1D Adults Using Continuous Glucose Monitoring Compared with Multiple Daily Insulin Injections: The DIAMOND Randomized Trial. Medical Decision Making, 2018, 38, 942-953.	2.4	12
44	Untangling the Black-White mortality gap in endometrial cancer: a cohort simulation. American Journal of Obstetrics and Gynecology, 2017, 216, 324-325.	1.3	22
45	The Role of the FDA and Regulatory Approval of New Devices for Diabetes Care. Current Diabetes Reports, 2017, 17, 40.	4.2	6
46	Assessing disruptions in adherence to antidepressant treatments after breast cancer diagnosis. Pharmacoepidemiology and Drug Safety, 2017, 26, 676-684.	1.9	6
47	Endocrine Therapy Initiation among Older Women with Ductal Carcinoma In Situ. Journal of Cancer Epidemiology, 2017, 2017, 1-6.	1.1	3
48	Reply to E. Ritchie et al. Journal of Clinical Oncology, 2017, 35, 1745-1746.	1.6	0
49	Pharmaceutical industry payments and oncologist drug selection.. Journal of Clinical Oncology, 2017, 35, 6510-6510.	1.6	0
50	The association between trajectories of endocrine therapy adherence and mortality among women with breast cancer. Pharmacoepidemiology and Drug Safety, 2016, 25, 953-959.	1.9	39
51	Socioeconomic Inequalities in Statin Adherence Under Universal Coverage. Circulation: Cardiovascular Quality and Outcomes, 2016, 9, 704-713.	2.2	32
52	Factors Associated With Tyrosine Kinase Inhibitor Initiation and Adherence Among Medicare Beneficiaries With Chronic Myeloid Leukemia. Journal of Clinical Oncology, 2016, 34, 4323-4328.	1.6	97
53	Cost-Utility Analysis of Cancer Prevention, Treatment, and Control. American Journal of Preventive Medicine, 2016, 50, 241-248.	3.0	48
54	Value of innovation in hematologic malignancies: a systematic review of published cost-effectiveness analyses. Blood, 2015, 125, 1866-1869.	1.4	32

#	ARTICLE	IF	CITATIONS
55	The Real World Effectiveness of Hematopoietic Transplant Among Elderly Individuals With Multiple Myeloma. Journal of the National Cancer Institute, 2015, 107, .	6.3	29
56	How Do Payers Respond to Regulatory Actions? The Case of Bevacizumab. Journal of Oncology Practice, 2015, 11, 313-318.	2.5	5
57	Cost-Utility Analyses in Diabetes: A Systematic Review and Implications from Real-World Evidence. Value in Health, 2015, 18, 308-314.	0.3	32
58	Cost-Effectiveness of Autologous Hematopoietic Stem Cell Transplantation for Elderly Patients with Multiple Myeloma using the Surveillance, Epidemiology, and End Resultsâ€“Medicare Database. Biology of Blood and Marrow Transplantation, 2015, 21, 1823-1829.	2.0	30
59	An Assessment of the Methodological Quality of Published Network Meta-Analyses: A Systematic Review. PLoS ONE, 2015, 10, e0121715.	2.5	28
60	Is the high cost of CML care "worth it"?. Journal of Clinical Oncology, 2015, 33, e17801-e17801.	1.6	1
61	Cost Sharing and Adherence to Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia. Journal of Clinical Oncology, 2014, 32, 306-311.	1.6	442
62	Health Utilities for Children and Adults With Type 1 Diabetes. Medical Care, 2011, 49, 924-931.	2.4	34
63	The Cost-Effectiveness of Continuous Glucose Monitoring in Type 1 Diabetes. Diabetes Care, 2010, 33, 1269-1274.	8.6	98